UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets

News provided by

Mar 04, 2015, 12:06 ET

BRISTOL, Tenn., March 4, 2015 /PRNewswire/ -- UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout has submitted an NDA intending for Flibanserin to be the first drug approved to treat hypoactive sexual desire disorder (HSDD), the most common form of female sexual dysfunction.

The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee.

Dr. John M. Gregory, Chairman and CEO of Gregory Pharmaceutical Holdings, Inc., said, "UPM's state of the art commercial manufacturing facility is ideal for the manufacturing and packaging with serialization of this product."

Cindy Whitehead, CEO of Sprout Pharmaceuticals, commented "Sprout was impressed with the broad production capabilities at UPM's facility as well as UPM's expertise in both manufacturing and packaging. Sprout believes that, upon approval, Flibanserin will provide the breakthrough that women's healthcare so richly deserves, and we are confident that UPM will be one of Sprout's valuable partners in the production and distribution of this first in class, first in disease treatment product."

About UPM Pharmaceuticals

UPM Pharmaceuticals, a wholly owned division of Gregory Pharmaceutical Holdings, Inc., is an independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. We provide high-quality drug development services including formulation development, cGMP clinical and commercial manufacturing, analytical methods development and stability testing. UPM's clients enjoy service that is customized and fast with total quality management characteristics of a customer-focused business. Our history includes successful collaborative interactions with small virtual and large billion-dollar companies providing customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets, and semi-solid creams and ointments. Our 475,000 square-foot commercial manufacturing facility based in Bristol, Tennessee allows us to serve our clients' needs from early stage development to large-scale commercial production.

About Sprout Pharmaceuticals

Sprout Pharmaceuticals is a company passionate about women's sexual health. With a breakthrough concept for women, the company "sprouted" out of Slate Pharmaceuticals in 2011. Based in Raleigh, NC, the company is focused solely on the delivery of a treatment option for the unmet need of women with HSDD. Sprout is pursuing FDA approval of Flibanserin to treat HSDD in premenopausal women, for which there is currently no FDA-approved treatment. For more information or the latest news about Sprout Pharmaceuticals, visit www.sproutpharma.com.

Forward-Looking Statements

Statements in this news release relating to the business of Sprout Pharmaceuticals which are not historical facts are "forward-looking statements". These forward-looking statements may be identified by words such as "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. The success of Flibanserin will depend upon its approval by the FDA and a host of other factors, both within and outside of Sprout Pharmaceuticals' control. These and other factors involve certain risks and uncertainties that could cause actual results to differ materially from Sprout Pharmaceuticals' views and expressions. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and neither UPM Pharmaceuticals nor Sprout Pharmaceuticals undertakes any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Logo - http://photos.prnewswire.com/prnh/20150304/179555LOGO

SOURCE UPM Pharmaceuticals